Alexza is interested in being a development partner for companies seeking an innovative, non-invasive IV-like systemic delivery method with exceptional ease of use for their novel compounds.
Compounds with poor solubility, low oral bioavailability, or high first pass metabolism can greatly benefit from using the Staccato® aerosol delivery system.
Alexza is interested in developing Staccato based products across all therapeutic areas. We have development programs available for partnering that are outside of our current therapeutic focus.
Leveraging development work that has already been completed, these programs are available for partnering and/or collaboration: